This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pritchett, E. L. C. Search for Related Content PubMed PubMed Citation Articles by Pritchett, E. L. C.

CLINICAL STUDY

Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response

Edward L. C. Pritchett, MD^a, Richard L. Page, MD, FACC^*, Stuart J. Connolly, MD, FACC, Stephen R. Marcello, MD, FACC, Daniel J. Schnell, PhD, William E. Wilkinson, PhD the Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators

^a Department of Medicine, Divisions of Cardiology and Clinical Pharmacology, Duke University Medical Center, Durham, North Carolina, USA
^* Department of Medicine, Cardiovascular Division, University of Texas Southwestern Medical Center, Parkland Memorial Hospital, Dallas, Texas, USA
Department of Medicine, McMaster University, Hamilton, Ontario, Canada
Procter and Gamble Pharmaceuticals, Cincinnati, Ohio, USA
Department of Community and Family Medicine, Division of Biometry, Duke University Medical Center, Durham, North Carolina, USA

Manuscript received July 2, 1999; revised manuscript received March 1, 2000, accepted April 13, 2000.

Reprint requests and correspondence: Dr. Edward L.C. Pritchett, Room 04280, Duke South Hospital, DUMC-3477, Durham, North Carolina 27710
ed.pritchett{at}duke.edu

OBJECTIVES

The purpose of this study was to assess the effectiveness of azimilide, a class III antiarrhythmic drug, in reducing the frequency of symptomatic arrhythmia recurrences in patients with atrial fibrillation, atrial flutter or both.

BACKGROUND

Atrial fibrillation is an increasingly common disorder of the heart rhythm, and most patients with this problem are identified because they have symptoms associated with their arrhythmia. New antiarrhythmic therapies are needed to treat patients with this problem.

METHODS

A total of 384 patients with a history of atrial fibrillation, atrial flutter or both were randomly assigned to receive once daily doses of placebo or azimilide; recurrent symptomatic arrhythmias were documented using transtelephonic electrocardiogram (ECG) recording. Azimilide 50 mg, 100 mg or 125 mg was tested; the primary efficacy analysis compared the time to first symptomatic recurrence in the combined azimilide 100 mg and 125 mg dose groups with that in the placebo group using the log-rank test.

RESULTS

In the primary efficacy analysis, the time to first symptomatic arrhythmia recurrence was significantly prolonged in the combined azimilide 100 mg and 125 mg daily dose group compared with the placebo group (chi-square 7.96, p = 0.005); the hazard ratio (placebo:azimilide) for this comparison was 1.58 (95% confidence interval [CI] = 1.15, 2.16). In comparisons between individual doses and placebo, the hazard ratio for the 50 mg daily dose was 1.17 (95% CI = 0.83, 1.66; p = 0.37); for the 100 mg group, dose was 1.38 (95% CI = 0.96, 1.98; p = 0.08), and for the 125 mg group, dose was 1.83 (95% CI = 1.24, 2.70; p = 0.002).

CONCLUSIONS

Azimilide significantly lengthened the symptomatic arrhythmia-free interval in patients with a history of atrial fibrillation, atrial flutter or both.

Abbreviations and Acronyms   AF = atrial fibrillation   BID = twice daily   CI = confidence interval   ECG = electrocardiogram   QD = daily

This article has been cited by other articles:

				A. P. Maggioni, G. Fabbri, D. Lucci, R. Marchioli, M. G. Franzosi, R. Latini, G. L. Nicolosi, M. Porcu, F. Cosmi, S. Stefanelli, et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial Eur. Heart J., October 1, 2009; 30(19): 2327 - 2336. [Abstract] [Full Text] [PDF]

				A. Arya, J. Silberbauer, S. L. Teichman, P. Milner, N. Sulke, and A. J. Camm A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology Europace, April 1, 2009; 11(4): 458 - 464. [Abstract] [Full Text] [PDF]

				I. Savelieva and J. Camm Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches Europace, June 1, 2008; 10(6): 647 - 665. [Abstract] [Full Text] [PDF]

				B. N. Singh and E. Aliot Newer antiarrhythmic agents for maintaining sinus rhythm in atrial fibrillation: simplicity or complexity? Eur. Heart J. Suppl., September 1, 2007; 9(suppl_G): G17 - G25. [Abstract] [Full Text] [PDF]

				K. M Dale and C M. White Dronedarone: An Amiodarone Analog for the Treatment of Atrial Fibrillation and Atrial Flutter Ann. Pharmacother., April 1, 2007; 41(4): 599 - 605. [Abstract] [Full Text] [PDF]

				F. Lombardi, M. Borggrefe, W. Ruzyllo, B. Luderitz, and for the A-COMET-II Investigators Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial Eur. Heart J., September 2, 2006; 27(18): 2224 - 2231. [Abstract] [Full Text] [PDF]

				Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 651 - 745. [Full Text] [PDF]

				V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society J. Am. Coll. Cardiol., August 15, 2006; 48(4): e149 - e246. [Full Text] [PDF]

				V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society Circulation, August 15, 2006; 114(7): e257 - e354. [Full Text] [PDF]

				C. M. Pratt, S. N. Singh, H. R. Al-Khalidi, J. M. Brum, M. J. Holroyde, S. R. Marcello, P. J. Schwartz, A. J. Camm, and ALIVE Investigators The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: Results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial J. Am. Coll. Cardiol., April 7, 2004; 43(7): 1211 - 1216. [Abstract] [Full Text] [PDF]

				I. Singer, H. Al-Khalidi, I. Niazi, P. Tchou, T. Simmons, R. Henthorn, M. Holroyde, and J. Brum Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators J. Am. Coll. Cardiol., January 7, 2004; 43(1): 39 - 43. [Abstract] [Full Text] [PDF]

				R. L. McNamara, L. J. Tamariz, J. B. Segal, and E. B. Bass Management of Atrial Fibrillation: Review of the Evidence for the Role of Pharmacologic Therapy, Electrical Cardioversion, and Echocardiography Ann Intern Med, December 16, 2003; 139(12): 1018 - 1033. [Abstract] [Full Text] [PDF]

				A. Capucci and D. Aschieri Antiarrhythmic drug therapy: what is certain and what is to come Eur. Heart J. Suppl., September 1, 2003; 5(suppl_H): H8 - H18. [Abstract] [PDF]

				P. Touboul, J. Brugada, A. Capucci, H. J.G.M. Crijns, N. Edvardsson, and S. H. Hohnloser Dronedarone for prevention of atrial fibrillation: A dose-ranging study Eur. Heart J., August 2, 2003; 24(16): 1481 - 1487. [Abstract] [Full Text] [PDF]

				R. L. Page, T. W. Tilsch, S. J. Connolly, D. J. Schnell, S. R. Marcello, W. E. Wilkinson, E. L.C. Pritchett, and for the Azimilide Supraventricular Arrhythmia Prog Asymptomatic or "Silent" Atrial Fibrillation: Frequency in Untreated Patients and Patients Receiving Azimilide Circulation, March 4, 2003; 107(8): 1141 - 1145. [Abstract] [Full Text] [PDF]

				P. Khairy and S. Nattel New insights into the mechanisms and management of atrial fibrillation Can. Med. Assoc. J., October 29, 2002; 167(9): 1012 - 1020. [Abstract] [Full Text] [PDF]

				M. R. Rosen Blunderbuss to Mickey Mouse: The Evolution of Antiarrhythmic Targets Circulation, September 3, 2002; 106(10): 1180 - 1182. [Full Text] [PDF]

				W. S. Aronow Management of the Older Person With Atrial Fibrillation J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2002; 57(6): M352 - 363. [Abstract] [Full Text]

				J. A. Reiffel Is it Rational, Reasonable or Excessive, and Consistently Applied? One View of the Increasing FDA Emphasis on Safety First for the Release and Use of Antiarrhythmic Drugs for Supraventricular Arrhythmias Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2001; 6(4): 333 - 339. [PDF]